Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Aurinia Pharmaceuticals

Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space?

Aurinia Pharmaceuticals (AUPH) released its third-quarter results, reporting solid revenue growth and robust cash flow from operations. Solid demand for its product offerings, restructuring strategies, and sound financials remain key drivers of the company’s growth and success. So, let’s analyze whether AUPH is a buy today. Read more to find…

Aurinia Pharmaceuticals Earns Relative Strength Rating Upgrade

Aurinia Pharmaceuticals Earns Relative Strength Rating Upgrade

Aurinia Pharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level.

Investors Business Daily

Aurinia Pharmaceuticals Stock Returns To A Rising Relative Strength

Aurinia Pharmaceuticals Stock Returns To A Rising Relative Strength

A Relative Strength Rating upgrade for Aurinia Pharmaceuticals shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Aurinia Pharmaceuticals Stock Shows Rising Relative Strength

Aurinia Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.

Investors Business Daily

Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout

Aurinia Pharmaceuticals said it's exploring strategic alternatives, including a potential buyout, leading AUPH stock to surge Friday.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread

Aurinia Pharmaceuticals hired a trio of executives in a move that suggests it's nowhere near a buyout — and AUPH stock plummeted Friday.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

PreMarket Prep Stock Of The Day: Good News From Aurinia Pharmaceuticals In A Down Week

PreMarket Prep Stock Of The Day: Good News From Aurinia Pharmaceuticals In A Down Week

Rarely mentioned in the recent chaos in the markets is the biotech sector. With a heavy emphasis in 2020 and 2021 on finding cures and treatments for COVID-19, major drug approvals from the FDA have been few and far between this year.

Earnings Preview For Aurinia Pharmaceuticals

Earnings Preview For Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (NASDAQ:AUPH) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Aurinia Pharmaceuticals will report an earnings per share (EPS) of $-0.27.

Analyst Ratings for Aurinia Pharmaceuticals

Analyst Ratings for Aurinia Pharmaceuticals

Analysts have provided the following ratings for Aurinia Pharmaceuticals (NASDAQ:AUPH) within the last quarter:

What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals

What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ:AUPH) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook

Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook

Aurinia topped fourth-quarter expectations Monday, but AUPH stock plummeted on lackluster guidance for lupus treatment Lupkynis.

Investors Business Daily

People

Joseph Schwartz

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Arista Networks

Medical Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play